Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Hamps Bio IPO
Hamps Bio Limited
₹1,02,000 /2000 sharesMinimum Investment
Hamps Bio IPO Listing Details
| Listed On | Issue Price | Listing Price | Listing Gains |
|---|---|---|---|
| -- | ₹51.00 | ₹96.90 | ₹45.90 (90.00%) |
Hamps Bio IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 13 Dec ‘24 - 17 Dec ‘24 | ₹1,02,000 | 2,000 | ₹51 - ₹51 |
| Issue Size | IPO Doc |
|---|---|
| 6.22Cr | RHP PDF |
About Hamps Bio
Founded in
2007
Managing director
Mr. Herrik Shah
Parent organisation
Hamps Bio Limited
Strengths & Financials of Hamps Bio
Strengths
Risks
As of October 31, 2024, Hamps Bio distributes its products through a network of over 50 distributors and various e-commerce platforms, including Amazon (US, Canada, Europe), Flipkart, and Jio Mart.
The company sells its pharmaceutical products in 8 states and Union Territories of India, while its freeze-dried and frozen products are marketed in 22 states and Union Territories and 6 countries. In total, Hamps Bio offers more than 180 different products across both segments.
Hamps Bio claims to have established 32 brands, offering over 100 products in the pharmaceutical segment, primarily targeting the domestic market.
The company is ISO 9001:2015 certified for quality management systems and ISO 22000:2018 certified for food safety management systems. The company also holds certifications from the US Food and Drug Administration (FDA) and the Food Safety and Standards Authority of India (FSSAI).
The company has seen a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 5.34 crore in FY22 to Rs 5.58 crore in FY23 to Rs 6.47 crore in FY24. Though small, PAT too increased from Rs 0.12 crore in FY22 to Rs 0.36 crore in FY23 to Rs 0.50 crore in FY24.
Hamps Bio is currently involved in certain ongoing legal proceedings. Any adverse judgments in any of these cases can be detrimental to the company’s business prospects.
The company does not have its own manufacturing facility for pharmaceutical products and relies on third-party manufacturers for procurement. The company does not have long-term agreements with these contract manufacturers. Any fall in the quality of products or delays in delivery from these manufacturers could adversely affect the company's operations.
The company's freeze-dried and frozen product manufacturing facility is located in a single region – Ankleshwar, Gujarat. Any disruption in this region could adversely affect the manufacturing facility, negatively affecting the company’s finances.
Hamps Bio’s revenue generation is dependent on its relationships with customers, with a major portion of revenue coming from the top 10 customers. These customers contributed Rs 1.29 crore (30.24%) for the period ending October 31, 2024, Rs 1.37 crore (21.13%), Rs 1.40 crore (25.05%) and Rs 0.90 crore (16.86%) to the revenue from operations in FY24, FY23, and FY22, respectively. The company does not have long-term contracts with these customers. So, a loss of any of these major customers or a decrease in business from them could harm the company’s business operations and finances.
A large part of the company’s revenue comes from clients in Gujarat. They contributed Rs 2.93 crore (68.80%) for the period ending October 31, 2024, and Rs 4.25 crore (65.70%), Rs 3.95 crore (70.76%) and Rs 3.81 crore (71.41%) to the revenue from operations in FY24, FY23, and FY22, respectively. Any adverse developments in the business environment of the region could adversely affect Hamps Bio’s operations and finances.
As of October 31, 2024, Hamps Bio had outstanding borrowings totalling Rs 1.38 crore. Any inability to repay or service these loans could adversely affect the company’s financial position.
Hamps Bio Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Hamps Bio IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹51 - 51 | ₹2 - 5 Lakh |
| High Networth Individual | ₹51 - 51 | ₹2 - 5 Lakh |
For Hamps Bio IPO, eligible investors can apply as Regular.